GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
Go back to GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting| (NASDAQ: GRAL) | Delayed: 61.88 -0.22 (0.35%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $62.10 | 52 Week High | $ | |||
| Open | $60.00 | 52 Week Low | $ | |||
| Day High | $63.82 | P/E | N/A | |||
| Day Low | $60.00 | EPS | $ | |||
| Volume | 264,864 | |||||
